There is currently no licensed vaccine for norovirus – commonly known as the winter vomiting bug – but are scientists getting closer to finally finding a jab that works? Volunteers are being recruited ...
On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...
The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...
Barchart on MSN1d
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
GlobalData on MSN3d
Moderna’s mRESVIA vaccine gains Health Canada approvalModerna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback